POLB

POLB encodes DNA polymerase β (pol β), a bifunctional enzyme central to base excision repair (BER) that carries two independently measurable catalytic activities — a dRP lyase activity and a gap-filling polymerase activity (PMID:39094983). It acts downstream of the DNA glycosylases OGG1 and NEIL1 to process BER intermediates, and genetic epistasis places loss of pol β activity as the cause of toxic intermediate accumulation that these glycosylases initiate (PMID:34186496). Loss-of-function POLB variants reduce polymerase activity and fail to rescue cells from alkylation (MMS) cytotoxicity, compromising BER and promoting genomic instability (PMID:22577134). In vivo, a hypomorphic slow-activity allele (Y265C) produces aberrant immune repertoire generation — shortened immunoglobulin heavy-chain junctions and elevated somatic hypermutation — and drives lupus-like autoimmune disease, an effect that is intrinsic to the hematopoietic compartment (PMID:24388753, PMID:35486639). Beyond its canonical nuclear role, pol β also localizes to mitochondria and contributes to mitochondrial BER and mtDNA integrity (PMID:29129598). Both the polymerase and lyase activities are required for a synthetic lethal interaction with PARP inhibition specifically in BRCA1/2-mutant cancer cells, where POLB loss combined with PARPi increases DNA breaks and apoptosis and drives tumor regression (PMID:40326293, PMID:39094983).

1. 2012 Medium

   Established that naturally occurring POLB mutations are functionally deleterious, linking reduced pol β polymerase activity to impaired BER and cancer-associated genomic instability.

   Evidence In vitro polymerase activity assays of colorectal tumor-derived POLB variants plus MMS cytotoxicity rescue in pol β-deficient cells

   PMID:22577134

   Open questions at the time

   • Causal contribution of these variants to tumor initiation in vivo not demonstrated
   • Effect on dRP lyase activity not separately measured
2. 2014 High

   Connected pol β catalytic activity during immune diversification to organismal disease, showing that a slow-activity allele drives autoimmunity via aberrant BER intermediates during immunoglobulin processing.

   Evidence Knock-in POLB-Y265C hypomorphic mouse with immunology, pathology, and Ig junction/somatic hypermutation readouts

   PMID:24388753

   Open questions at the time

   • Molecular identity of the toxic BER intermediates not directly characterized
   • Cell type driving autoimmunity not yet localized at this stage
3. 2017 Medium

   Extended pol β's functional compartment beyond the nucleus by demonstrating mitochondrial localization and a role in mitochondrial BER and mtDNA integrity.

   Evidence Subcellular fractionation and functional mitochondrial studies summarized from two independent groups

   PMID:29129598

   Open questions at the time

   • Import mechanism into mitochondria not defined
   • Relative contribution of nuclear vs. mitochondrial pol β to phenotypes unresolved
4. 2021 Medium

   Ordered pol β within the BER pathway by genetic epistasis, placing it downstream of OGG1 and NEIL1 and showing that removing upstream glycosylases relieves toxic intermediate accumulation.

   Evidence Double-knockout mice (PolbY265C crossed with Ogg1 and Neil1 KOs) with antinuclear antibody and renal disease readouts

   PMID:34186496

   Open questions at the time

   • Microhomology-mediated end-joining defect mechanism not biochemically dissected
   • Whether other glycosylases contribute remains untested
5. 2022 Medium

   Localized the disease-driving cell compartment by showing the hematopoietic system is sufficient to transfer pol β-deficiency lupus.

   Evidence Bone marrow transplantation from PolbY265C/C mice into wild-type recipients with serology and histopathology

   PMID:35486639

   Open questions at the time

   • Specific hematopoietic lineage responsible not pinpointed
   • Whether non-hematopoietic pol β modifies disease not addressed
6. 2024 Medium

   Biochemically resolved pol β's two catalytic activities into independently measurable lyase and polymerase functions, enabling activity-specific dissection.

   Evidence SAMDI mass spectrometry duplexed enzymatic assay, fluorescence strand-displacement assay, and affinity-selection MS binding assay

   PMID:39094983

   Open questions at the time

   • Single-lab assay development without independent confirmation
   • Coordination between the two activities in vivo not addressed
7. 2024 Low

   Reported a pro-apoptotic effect of POLB overexpression linked to the intrinsic apoptosis pathway in a non-canonical model system.

   Evidence POLB overexpression and siRNA knockdown in bovine primary myocytes with apoptosis assays and CASP9 expression

   PMID:38731327

   Open questions at the time

   • Single lab, single bovine myocyte system without orthogonal validation
   • Mechanistic link between pol β and CASP9 induction undefined
   • Relevance to human pol β biology unestablished
8. 2025 High

   Defined a therapeutically actionable vulnerability by showing pol β is synthetic lethal with PARP inhibition in BRCA1/2-mutant cancers and that both catalytic activities are required.

   Evidence CRISPR KO screen, catalytically inactive mutant overexpression in isogenic BRCA1/2 cell lines, DNA damage quantification, and niraparib xenograft models

   PMID:40326293

   Open questions at the time

   • Precise molecular basis of the BRCA-specific dependence not fully mapped
   • Resistance mechanisms and clinical translatability untested

• How pol β's nuclear and mitochondrial BER functions are coordinated, and how its dual catalytic activities are mechanistically partitioned across immune repertoire generation, autoimmunity, and the BRCA synthetic lethal context, remains unresolved.
• No structural model linking dual activities to substrate handoff in the timeline
• Mitochondrial import and regulation uncharacterized
• Direct molecular partners in BER complexes not defined in the corpus